Workgroup Software Demo Webinar: Part 4
March 25, 2014
A 16-minute Introduction to Caristix Workgroup: Part Four Ready for the next piece of our 16-minute webinar on Caristix Workgroup? Learn what Workgroup can do
A 16-minute Introduction to Caristix Workgroup: Part Four Ready for the next piece of our 16-minute webinar on Caristix Workgroup? Learn what Workgroup can do
A 16-minute Introduction to Caristix Workgroup: Part Three Not much time? That’s why we’re offering our 16-minute webinar on Caristix Workgroup Software in small easy-to-consume
A 16-minute Introduction to Caristix Workgroup: Part Two We know you’re busy. That’s why we’re offering our 16-minute webinar on Caristix Workgroup Software in bite-sized
A 16- minute Introduction to Caristix Workgroup Software We’ve just developed a quick on-demand webinar that gives you the opportunity to take a bird’s-eye view
Announcing Caristix Converters We gave you a sneek peak at our new Caristix technology, converters, in a previous blog post, Cutting Interface Costs, Continued. In
Are you just getting started with Caristix software? Or do you need a refresh on functionality you haven’t used in a while? We’re launching a
A sneak peek at new Caristix technology A few weeks ago, we published an article on the cost of interfaces. We’ve also ranted a little,
Workgroup Bug fixes Several corrections to the HL7 v2.7 reference profile Enhancements Sort, Create New Folder, and Refresh Library are available through a right-click contextual
Here’s Our Quick Take on What’s Coming Up in 2014 Meaningful Use Stage 2 and ICD-10 implementation are going to be big headaches for providers
Have a wonderful holiday season and wishing you the best for 2014!
NORTH AMERICA: +1 (877)-872-0027
WORLD: 1-418-872-4000
EMAIL: info@caristix.com
ASIA-PACIFIC
DENIS CANTIN
T: +61418441388
denis.cantin@caristix.com
NORTH AMERICA & EUROPE
JEAN-LUC MORIN
T: 418 872-4000
jeanluc.morin@caristix.com
HL7® / FHIR® are a registered trademarks of Health Level Seven International. The use of this trademark does not constitute an endorsement by HL7.